The news highlights significant progress in Nektar's drug development pipeline, which is crucial for the company's future growth. The anticipation of phase 2 results for rezpegaldesleukin and promising results from NKTR-255 in oncology trials are positive indicators. The potential near-term readout in the JAVELIN Bladder Medley study could further impact the stock positively, despite existing competition.